Henan Newland Pharmaceutical Co. Ltd. A Asset Resilience Ratio
Henan Newland Pharmaceutical Co. Ltd. A asset resilience ratio. Henan Newland Pharmaceutical Co. Ltd. A (301277) has an Asset Resilience Ratio of 29.76% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of Henan Newland Pharmaceutical Co. Ltd. A to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Henan Newland Pharmaceutical Co. Ltd. A (2021–2025)
Asset resilience ratio of Henan Newland Pharmaceutical Co. Ltd. A from 2021 to 2025. This chart shows how Henan Newland Pharmaceutical Co. Ltd. A's Asset Resilience Ratio has changed over time. Read Henan Newland Pharmaceutical Co. Ltd. A (301277) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Henan Newland Pharmaceutical Co. Ltd. A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Henan Newland Pharmaceutical Co. Ltd. A.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥542.35 Million | 29.76% |
| Total Liquid Assets | CN¥542.35 Million | 29.76% |
Asset Resilience Insights
- Very High Liquidity: Henan Newland Pharmaceutical Co. Ltd. A maintains exceptional liquid asset reserves at 29.76% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Henan Newland Pharmaceutical Co. Ltd. A Industry Peers by Asset Resilience Ratio
Compare Henan Newland Pharmaceutical Co. Ltd. A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Sandoz Group AG
SW:SDZ |
Drug Manufacturers - Specialty & Generic | 7.89% |
|
H Lundbeck A/S
CO:HLUN-B |
Drug Manufacturers - Specialty & Generic | -0.56% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Viyash Scientific Limited
NSE:SEQUENT |
Drug Manufacturers - Specialty & Generic | 0.08% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
Henan Newland Pharmaceutical Co. Ltd. A Asset Resilience Ratio by Year (2021–2025)
Henan Newland Pharmaceutical Co. Ltd. A asset resilience ratio by year from 2021 to 2025. The table below shows the annual Asset Resilience Ratio data for Henan Newland Pharmaceutical Co. Ltd. A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 30.88% | CN¥549.55 Million ≈ $80.42 Million |
CN¥1.78 Billion ≈ $260.40 Million |
+1.93pp |
| 2024-12-31 | 28.95% | CN¥525.16 Million ≈ $76.85 Million |
CN¥1.81 Billion ≈ $265.41 Million |
-7.67pp |
| 2023-12-31 | 36.63% | CN¥589.50 Million ≈ $86.26 Million |
CN¥1.61 Billion ≈ $235.52 Million |
-9.10pp |
| 2022-12-31 | 45.73% | CN¥701.36 Million ≈ $102.63 Million |
CN¥1.53 Billion ≈ $224.44 Million |
+44.43pp |
| 2021-12-31 | 1.30% | CN¥8.67 Million ≈ $1.27 Million |
CN¥667.90 Million ≈ $97.74 Million |
-- |
About Henan Newland Pharmaceutical Co. Ltd. A
Newland Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates and APIs in China. The company offers pharmaceutical intermediates, including L-4-hydroxyphenylglycine methyl ester, L-hydroxyphenylglycine potassium salt, L-4-hydroxyphenylglycine, and p-Toluenesulfonic acid. It also provides APIs, such as ropivacaine hydrochloride, naph… Read more